These data demonstrate that TINO is a broadly active antitumor agent in vitro and in vivo, with potent radio-sensitizing activity in aggressive and TMZ-resistant glioblastoma tumor models, supporting ongoing clinical evaluation of this compound in combination with RT for the treatment of post-surgery glioblastoma patients. Here, MEX3D is linked to neoplasm.